Work

Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance

Year: 2012

Type: article

Abstract: Summary: The clinical success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Two reports in this issue of Cancer Discovery uncover additional mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment. These findings pave the way for clinical testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic. Cancer Discov; 2(10); 872–5. ©2012 AACR. Commentary on Ercan et al., p. 934. Commentary on Takezawa et al., p. 922.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-12-0387

Authors: Collin M. Blakely, Trever G. Bivona

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute